Neuromyelitis Optica Spectrum Disorder News and Research

RSS

Blacks, Latinos with autoimmune diseases experience poorer outcomes due to modifiable social conditions

Minority populations in the US with multiple sclerosis and other autoimmune diseases experience poorer outcomes due to modifiable social conditions, according to a new USC study.

5 Oct 2021

New research may offer clues to why MS patients develop progressive disability

Did you know multiple sclerosis (MS) means multiple scars? New research shows that the brain and spinal cord scars in people with MS may offer clues to why they developprogressive disability but those with related diseases where the immune system attacks the central nervous system do not.

19 Jul 2021

Dying patients with rare diseases struggle to get experimental therapies

At 15, Autumn Fuernisen is dying. She was diagnosed at age 11 with a rare degenerative brain disorder that has no known cure or way to slow it down: juvenile-onset Huntington's disease.

14 Jul 2021

Researchers develop a classification scheme for neuromyelitis optica spectrum disorder

Researchers in the Department of Neurology at Tohoku University, which is led by professor Masashi Aoki, have developed a classification scheme for neuromyelitis optica spectrum disorder, a rare autoimmune disease that until recently was thought to be a type of multiple sclerosis (MS).

15 Apr 2021

FDA approves drug for treatment of neuromyelitis optica spectrum disorder

The U.S. Food and Drug Administration has approved Enspryng (satralizumab-mwge) for the treatment of neuromyelitis optica spectrum disorder (NMOSD) in adults with a particular antibody - patients who are anti-aquaporin-4 or AQP4 antibody-positive.

17 Aug 2020

Study: Certain inflammatory demyelinating diseases belong to different category than multiple sclerosis

An antibody appears to make a big difference between multiple sclerosis and other disorders affecting the protective myelin sheath around nerve fibers, report Tohoku University scientists and colleagues in the journal Brain.

19 May 2020

Cytel hosts Complex Innovative Trial Design Symposium and East Training in Boston

Cytel Inc., the leading global provider of innovative analytical software and consulting services to the life sciences industry, has announced that the Complex Innovative Trial Design Symposium and East Training will take place November 6–7 at Alexion’s headquarters in Boston, Massachusetts.

From Cytel 18 Oct 2019

Neuromyelitis Optica Spectrum Disorder News and Research

Blacks, Latinos with autoimmune diseases experience poorer outcomes due to modifiable social conditions

New research may offer clues to why MS patients develop progressive disability

Dying patients with rare diseases struggle to get experimental therapies

Researchers develop a classification scheme for neuromyelitis optica spectrum disorder

FDA approves drug for treatment of neuromyelitis optica spectrum disorder

Study: Certain inflammatory demyelinating diseases belong to different category than multiple sclerosis

Cytel hosts Complex Innovative Trial Design Symposium and East Training in Boston

FDA approves first drug for treatment of neuromyelitis optica spectrum disorder

Drug reduces risk of relapse with neuromyelitis optica spectrum disorder, study shows

Alexion announces positive results from Phase 3 PREVENT study of Soliris in patients with NMOSD

Study highlights possible reasons for MS misdiagnosis

International consensus panel reviews new diagnostic criteria for neuromyelitis optica spectrum disorder

Expanding research and clinical options for children with cancer

Examining how pain could play a direct protective role in the gut

From Puberty to Menopause: Clue’s CEO, Audrey Tsang on the Power of Femtech

Latest News